Savvy Updates 5/22/23: Beta Bionics iLet Bionic Pancreas Approved, GLP-1 / Anticancer?, No More Sugar Substitutes, Bad News Can Make You Sick, Almonds as Healthy Snack
FDA Clears iLet Bionic Pancreas System for Type 1 Diabetes by Kristen Monaco for MedPageToday.com, 19 May 2023. The new iLet Bionic Pancreas system was cleared by the FDA for patients 6 and older with type 1 diabetes, the agency...
Savvy Updates, 5/15/23: Know Labs Study, TIR & Young T1Ds & Insulins, Insulin Resistance, Capsule Studies Microbiome, Insulin Temp Stability, Watermelon Heart-Healthy, Embecta/Tidepool Partner for T2D, Glucomate, Diabetes Epidemic in UK, Legislation to Fix Prior Auth
Know Labs reports data from feasibility study of Bio-RFID sensor reported on MedicalDevice-Network.com, 8 May 2023. Know Labs has reported data from a new technical feasibility study of its Bio-RFID sensor technology for non-invasive glucose monitoring, compared to...
Savvy Updates, 5/8/23: CGM Disruptions (Dexcom & Abbott), Japanese Diet & NAFLD, UPFs & Brain Health, Weight Loss Drug $$, Envision Bankruptcy
Most adults with diabetes report CGM disruptions due to device problems, medical care by Alexis McKee for Healio.com/endocrinology, 3 May 2024. More than 80% of adults with diabetes using continuous glucose monitoring reported at least one instance of...
Savvy D Living, 5/3/23: TCOYD on Carbs, Digestive Organs Vary, T1D in Hospital, T1D and Teeth, Burden of T1D Living, About Hair
TCOYD: All about Carb Counting with Drs. Steve Edelman and Jeremy Pettus These are 2 great videos (among many others) by TCOYD about carbs, carb counting and how to count fiber in your carb counting. I’ve always said that T1D would be WAY easier to manage...
Savvy Updates 5/1/23: Lilly Sells Off Baqsimi, Humacyte Biovascular Pancreas, Dexcom Growth, Know Labs Non-Invasive Sensor, Medtronic Resolves FDA Warning Letter, Omnipod GO for T2D, Doctors More Neurotic, Diabetes Standards of Care, 2023
Lilly sells emergency diabetes drug for $500M by Jonathan Gardner for BioPharmaDive.com, 24 April 2023. Eli Lilly will sell its emergency diabetes treatment Baqsimi to Amphastar Pharmaceuticals for $500 million upfront, the company said, divesting a drug launched...
More Diabetes Blogs